JP2009531313A - （５ｓ）−５−［４−（５−クロロ−ピリジン−２−イルオキシ）−ピペリジン−１−スルホニルメチル］−５−メチル−イミダゾリジン−２，４−ジオン（ｉ）の新規結晶形ｇおよびその中間体 - Google Patents

（５ｓ）−５−［４−（５−クロロ−ピリジン−２−イルオキシ）−ピペリジン−１−スルホニルメチル］−５−メチル−イミダゾリジン−２，４−ジオン（ｉ）の新規結晶形ｇおよびその中間体 Download PDF

Info

Publication number
JP2009531313A
JP2009531313A JP2009500326A JP2009500326A JP2009531313A JP 2009531313 A JP2009531313 A JP 2009531313A JP 2009500326 A JP2009500326 A JP 2009500326A JP 2009500326 A JP2009500326 A JP 2009500326A JP 2009531313 A JP2009531313 A JP 2009531313A
Authority
JP
Japan
Prior art keywords
methyl
imidazolidine
dione
yloxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531313A5 (enExample
Inventor
ニール・バーンウェル
ラーシュ−エリク・ブリッグナー
アンドレア・コール
アンデシュ・エリクソン
ジェイコブ・パーキンス
ルイ−マヌエル・ヴァズ
アンドリュー・ウェルズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38509897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009531313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2009531313A publication Critical patent/JP2009531313A/ja
Publication of JP2009531313A5 publication Critical patent/JP2009531313A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009500326A 2006-03-16 2007-03-15 （５ｓ）−５−［４−（５−クロロ−ピリジン−２−イルオキシ）−ピペリジン−１−スルホニルメチル］−５−メチル−イミダゾリジン−２，４−ジオン（ｉ）の新規結晶形ｇおよびその中間体 Pending JP2009531313A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78297906P 2006-03-16 2006-03-16
PCT/SE2007/000256 WO2007106022A2 (en) 2006-03-16 2007-03-15 A new crystalline form g of (5s) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (i) and intermediates thereof.

Publications (2)

Publication Number Publication Date
JP2009531313A true JP2009531313A (ja) 2009-09-03
JP2009531313A5 JP2009531313A5 (enExample) 2010-04-15

Family

ID=38509897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500326A Pending JP2009531313A (ja) 2006-03-16 2007-03-15 （５ｓ）−５−［４−（５−クロロ−ピリジン−２−イルオキシ）−ピペリジン−１−スルホニルメチル］−５−メチル−イミダゾリジン−２，４−ジオン（ｉ）の新規結晶形ｇおよびその中間体

Country Status (16)

Country Link
US (1) US20090221640A1 (enExample)
EP (1) EP2064202A4 (enExample)
JP (1) JP2009531313A (enExample)
KR (1) KR20090008229A (enExample)
CN (1) CN101448819A (enExample)
AR (1) AR059913A1 (enExample)
AU (1) AU2007225477A1 (enExample)
BR (1) BRPI0709579A2 (enExample)
CA (1) CA2644345A1 (enExample)
CL (1) CL2007000680A1 (enExample)
IL (1) IL193670A0 (enExample)
MX (1) MX2008011641A (enExample)
NO (1) NO20084282L (enExample)
TW (1) TW200800954A (enExample)
UY (1) UY30214A1 (enExample)
WO (1) WO2007106022A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
JP5838226B2 (ja) 2011-01-13 2016-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート誘導体の製造方法
EP2797881B1 (en) 2011-12-27 2018-11-14 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
WO2014178433A1 (ja) 2013-05-02 2014-11-06 株式会社エーピーアイ コーポレーション α－置換システインもしくはその塩又はα－置換システイン合成中間体の製造方法
CN116033902A (zh) 2020-06-26 2023-04-28 伯明翰大学 治疗脊髓损伤或相关神经组织损伤的方法
CN114133337A (zh) * 2020-12-14 2022-03-04 成都泰蓉生物科技有限公司 一种2-取代的赖氨酸的制备方法
CN117820178A (zh) * 2023-12-26 2024-04-05 山东泰和科技股份有限公司 一种d,l-蛋氨酸的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527515A (ja) * 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤
JP2004527511A (ja) * 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6172762A (ja) * 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
GB8618559D0 (en) * 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) * 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) * 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) * 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
NL9201230A (nl) * 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
TW514634B (en) * 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
CN1665803A (zh) * 2002-04-30 2005-09-07 特瓦药厂有限公司 新晶形的昂丹司琼及其制备方法、含有该新晶形的药物组合物以及用其治疗恶心的方法
CN1665504A (zh) * 2002-05-10 2005-09-07 特瓦制药工业有限公司 新晶型的加替沙星
KR20050010826A (ko) * 2002-06-05 2005-01-28 가부시키가이샤 가네카 광학 활성 α-메틸시스테인 유도체의 제조 방법
US20040266832A1 (en) * 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527515A (ja) * 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤
JP2004527511A (ja) * 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012041156; Ｃ．Ｇ．ＷＥＲＭＵＴＨ編、「最新創薬化学　下巻」、株式会社テクノミック、平成１１年９月２５日、ｐ．４５２-４５３ *
JPN6012041157; 岡野定舗編著、「新・薬剤学総論（改訂第３版）」、株式会社南江堂、１９８７年４月１０日、ｐ．１１１ *
JPN6012041159; 社団法人日本化学会、「新実験化学講座１　基本操作Ｉ」、丸善株式会社、昭和５３年３月２０日第３刷、ｐ．３１８-３１９ *
JPN6012041160; 緒方章著、「化学実験操作法　上巻」、株式会社南江堂、昭和３８年１１月２０日第２７版、ｐ．３９１ *

Also Published As

Publication number Publication date
AR059913A1 (es) 2008-05-07
EP2064202A2 (en) 2009-06-03
NO20084282L (no) 2008-10-13
TW200800954A (en) 2008-01-01
EP2064202A4 (en) 2011-01-12
CA2644345A1 (en) 2007-09-20
CL2007000680A1 (es) 2008-02-08
KR20090008229A (ko) 2009-01-21
WO2007106022A2 (en) 2007-09-20
BRPI0709579A2 (pt) 2011-07-19
WO2007106022A3 (en) 2007-11-01
UY30214A1 (es) 2007-10-31
MX2008011641A (es) 2008-09-22
AU2007225477A1 (en) 2007-09-20
US20090221640A1 (en) 2009-09-03
CN101448819A (zh) 2009-06-03
IL193670A0 (en) 2009-05-04

Similar Documents

Publication Publication Date Title
JP2009531313A (ja) （５ｓ）−５−［４−（５−クロロ−ピリジン−２−イルオキシ）−ピペリジン−１−スルホニルメチル］−５−メチル−イミダゾリジン−２，４−ジオン（ｉ）の新規結晶形ｇおよびその中間体
CN1149190C (zh) 一氧化氮合成酶抑制剂
US9643927B1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
KR100853049B1 (ko) 산화질소 신타제 억제제 포스페이트염
EP2649060B1 (en) Process for the preparation of benzimidazole derivatives and its salts
TWI406661B (zh) ４-甲基-ｎ-〔３-（４-甲基-咪唑-１-基）-５-三氟甲基-苯基〕-３-（４-吡啶-３-基-嘧啶-２基胺基）-苯甲醯胺之結晶型
CN103080078B (zh) 光学活性二胺衍生物盐的制备方法
JP2011509916A (ja) チアゾリジン誘導体およびその製造方法
CN1056141C (zh) 哌嗪衍生物
US10550087B2 (en) Process for the preparation of kinase inhibitors and intermediates thereof
SK18052000A3 (sk) Amidínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
HUT74103A (en) Aroyl-piperidine derivative
CN1141043A (zh) 非肽类速激肽受体拮抗剂
CN1129941A (zh) 取代的氮杂二氢亚吲哚基化合物及其制备方法
US20150011589A1 (en) Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP3492452B1 (en) Production method for pyrazole-amide compound
KR20000005505A (ko) 피페리딘 및 피롤리딘
US20050228017A1 (en) Novel anticancer compounds
CN116018337A (zh) 铜绿假单胞菌毒力因子LasB抑制剂
CN1610674A (zh) 2－氨基－二氢噻唑衍生物及其作为诱导型no－合酶抑制剂的用途
EP4357335A1 (en) Azabicyclo[3.1.0]hexane compound
JP2006188505A (ja) インドール類の製造方法および製造中間体
HK1100442A (en) Butyrylcholinesterase selective inhibitors
HK1057868A (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507